ClinicalTrials.gg
TerminatedNCT04022915Updated Mar 18, 2026Results posted

PET Fibrin Imaging of DVT and PE

A Phase 1 interventional study of 64Cu-FBP8 and PET-CT imaging in Pulmonary Embolism, Deep Vein Thrombosis and Venous Thromboembolism, sponsored by Peter Caravan. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Peter Caravan · Phase 1, Interventional, and Diagnostic

How we know

Why this study was terminated
The study did not reach its enrollment target due to a relatively narrow time window for imaging after the contrast CT imaging confirmed PE and limitations in the availability of the tracer and the PET scanner.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Pulmonary Embolism with a site in United States — 34 open to participants now, 43 under way, 6 of them phase 3. Pulmonary Embolism · United States.

Enrollment
151st of 166
6 · median 142
Started
2019
with 9 others
Phase 1
14 of 236
2 open now
Registered
153rd of 236
by date

Among the 236 studies in Pulmonary Embolism with a site in United States, this one is the 151st largest by enrollment of the 166 interventional ones that give a count, is one of 10 that started in 2019, is one of 14 in phase 1, and was the 153rd registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

34 of the 236 studies in Pulmonary Embolism with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Pulmonary Embolism with a site in United States, or all of them as a file.
02

Study summary

This study aims to investigate a novel positron emission tomography(PET)-probe for imaging of fresh intravascular blood clots in pulmonary embolism (PE) and deep venous thrombosis (DVT).

Read the detailed description

Venous thromboembolism (VTE) is one of the most common causes of death in the United States, resulting in more than 100,000 deaths annually. Current diagnostic techniques rely on indirect measures of clot for diagnosis and therefore suffer from the problems of both under and overdiagnosis and cannot always be performed on patients with renal failure and lung disease. In this study, we will use the novel fibrin-specific probe 64CU-FBP8 (Copper-64 labeled fibrin binding probe 8) for PET imaging of fresh blood clots in PE and DVT. Our long-term goal is to establish a novel thrombus body scan (TBS) using 64CU-FBP8 for PET imaging to overcome the limitations of indirect venous thromboembolism diagnosis, and, with one single test, provide a total-body assessment of fresh intravascular clot.

03

Conditions studied

  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Venous Thromboembolism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older with a pulmonary embolus (PE) confirmed by a filling defect in CT angiography (CTA), and
  • Subjects must receive the radiotracer injection within 72 hours of their diagnosis.

Exclusion criteria

Exclusion Criteria:

  • Subjects \< 18 years of age
  • Time of expected radiotracer injection > 72 hours from the time of a positive venous duplex ultrasound or CT- angiogram
  • Women subjects of who are pregnant, seeking to become pregnant, or have a positive serum pregnancy (beta-HCG) test
  • Unable to lie flat for 45 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis, dyspnea),
  • Weight that exceeds the PET camera table limit (300 kg)
  • The subject will not be enrolled in the study if the radiation exposure for research studies during the prior 12 months, combined with the exposure from this study would exceed 50 mSv (millisievert).
  • Due to the radiation exposure from imaging studies, all women of childbearing potential will be required to have a negative serum pregnancy test performed prior to any imaging procedures on the same day (if not already done that day). Patients with a positive serum pregnancy test will be excluded. Breast feeding women will also be excluded.
  • A pre-existing condition or use of a medication including vasopressors and tPA (tissue Plasminogen Activator) that in the opinion of the investigator may place the subject at a substantially increased risk
  • Hemodynamic instability, including requiring escalating doses of vasopressor medication.
  • No groups designated as "special vulnerable populations" will be studied.
  • No exclusions will be made based on race, sex, or ethnic origin.
  • 64Cu-FBP8 (Copper-64 labeled fibrin binding probe 8) is cleared by the kidneys, patients with (estimated Glomerular Filtration Rate ) \< 30 will be excluded.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Acute pulmonary embolism

    Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.

    Drug: 64Cu-FBP8 · Diagnostic Test: PET-CT imaging

Interventions

  • DrugCopper Cu 64 FBP8Studies of Copper Cu 64 FBP8Copper Cu 64 FBP8 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Up to 10 mCi (millicurie) 64Cu-FBP8 will be administered to each subject.

  • Diagnostic testPET-CT imaging

    All subjects will undergo PET-CT imaging after administration of 64Cu-FBP8.

06

What researchers measure

Primary outcomes

  1. Location of the Thrombus Within the Lungs

    To determine the location of the thrombus regions of interest (ROIs) within the lungs using PET-CT imaging in comparison to the ROI of filling defects on CT-angiogram.

    Time frame: 72 hours

  2. Location of Clot Burden Measurements Within the Thigh

    To determine the location of the thrombus ROI within the thigh using PET-CT imaging in comparison to the clot on venous duplex ultrasound.

    Time frame: 72 hours

  3. Assessment of 64Cu-FBP8 Fibrin Activity in the Pelvic Veins and Upper Extremity

    The presence or absence of blood clots as assessed by high 64Cu-FBP8 fibrin activity in the pelvic veins and upper extremities will be reported.

    Time frame: 4 hours

Secondary outcomes

  1. Correlation Between Normalized 64Cu-FBP8 Fibrin Activity and Plasma D-dimer

    Correlation of the total fibrin activity in the imaged fields, excluding the liver, gallbladder, kidneys and urinary bladder normalized by injected dose with the plasma D-dimer. Outcome measure is the value of the Pearson correlation coefficient .

    Time frame: 4 hours

  2. Overall Clot Burden Within the Lungs

    Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the lungs. This is reported in 4 different ways: 1. TBRmean of the PE which is the ratio of the mean PET signal in the pulmonary embolus (clot) divided by the mean PET signal in the blood pool 2. TBRmax of the PE which is the ratio of the maximum PET signal in the pulmonary embolus (clot) divided by the mean PET signal in the blood pool 3. SUVmean of the PE which is the mean standardized uptake value (SUV) in the pulmonary embolus (clot) 4. SUVmax of the PE which is the maximum standardized uptake value (SUV) in the pulmonary embolus (clot)

    Time frame: 4 hours

  3. Overall Clot Burden Within the Thigh

    Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the thigh. This is reported as: TBRmean of the thrombus which is the ratio of the mean PET signal in the thrombus within the thigh divided by the mean PET signal in the blood pool

    Time frame: 4 hours

07

Results

Posted Mar 18, 2026

Participant flow

Participants were recruited between May 2018 and August 2022 based on a PE diagnosis confirmed by CT pulmonary angiogram (CTPA).

Participant flow — Overall Study
MilestoneAcute Pulmonary Embolism
Started6
Completed5
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryLocation of the Thrombus Within the Lungs

To determine the location of the thrombus regions of interest (ROIs) within the lungs using PET-CT imaging in comparison to the ROI of filling defects on CT-angiogram.

Time frame:
72 hours
Reported as:
Count of participants · Participants
Location of the Thrombus Within the Lungs
ParticipantsAcute Pulmonary Embolism
Blood clots in same left-right lung location in PET and CTPA2
Blood clots in same left-right lung location in PET as in CTPA and on the other side2
No blood clots in PET1
PrimaryLocation of Clot Burden Measurements Within the Thigh

To determine the location of the thrombus ROI within the thigh using PET-CT imaging in comparison to the clot on venous duplex ultrasound.

Time frame:
72 hours
Reported as:
Count of participants · Participants
Location of Clot Burden Measurements Within the Thigh
ParticipantsAcute Pulmonary Embolism
No evidence for clots5
Evidence for clots0
PrimaryAssessment of 64Cu-FBP8 Fibrin Activity in the Pelvic Veins and Upper Extremity

The presence or absence of blood clots as assessed by high 64Cu-FBP8 fibrin activity in the pelvic veins and upper extremities will be reported.

Time frame:
4 hours
Reported as:
Count of participants · Participants
Assessment of 64Cu-FBP8 Fibrin Activity in the Pelvic Veins and Upper Extremity
ParticipantsAcute Pulmonary Embolism
No evidence for clots5
Evidence for clots0
SecondaryCorrelation Between Normalized 64Cu-FBP8 Fibrin Activity and Plasma D-dimer

Correlation of the total fibrin activity in the imaged fields, excluding the liver, gallbladder, kidneys and urinary bladder normalized by injected dose with the plasma D-dimer. Outcome measure is the value of the Pearson correlation coefficient .

Time frame:
4 hours
Reported as:
Number · Pearson correlation coefficient
Correlation Between Normalized 64Cu-FBP8 Fibrin Activity and Plasma D-dimer
Pearson correlation coefficientAcute Pulmonary Embolism
Correlation Between Normalized 64Cu-FBP8 Fibrin Activity and Plasma D-dimer0
SecondaryOverall Clot Burden Within the Lungs

Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the lungs. This is reported in 4 different ways: 1. TBRmean of the PE which is the ratio of the mean PET signal in the pulmonary embolus (clot) divided by the mean PET signal in the blood pool 2. TBRmax of the PE which is the ratio of the maximum PET signal in the pulmonary embolus (clot) divided by the mean PET signal in the blood pool 3. SUVmean of the PE which is the mean standardized uptake value (SUV) in the pulmonary embolus (clot) 4. SUVmax of the PE which is the maximum standardized uptake value (SUV) in the pulmonary embolus (clot)

Time frame:
4 hours
Reported as:
Mean · Unitless ratio
Overall Clot Burden Within the Lungs
Unitless ratioAcute Pulmonary Embolism
TBRmean of the PE15.07 (10.86 to 22.35)
TBRmax of the PE23.23 (14.05 to 31.66)
SUVmean of the PE1.420 (0.708 to 1.743)
SUVmax of the PE2.098 (1.497 to 2.499)
SecondaryOverall Clot Burden Within the Thigh

Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the thigh. This is reported as: TBRmean of the thrombus which is the ratio of the mean PET signal in the thrombus within the thigh divided by the mean PET signal in the blood pool

Time frame:
4 hours
Reported as:
Mean · Unitless ratio
Overall Clot Burden Within the Thigh
Unitless ratioAcute Pulmonary Embolism
Overall Clot Burden Within the Thigh0 ± 0

Adverse events

Collected over After 64Cu-FBP8 injection, during PET imaging, and 24 hours monitoring. The all-cause mortality is based on the last follow-up after 12 months, including the participant who withdrew from the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acute Pulmonary Embolism2/6 (33.3%)0/6 (0%)0/6 (0%)

Baseline characteristics

Including all recruited participants.

Age, Continuous
Age, Continuous(years)Acute Pulmonary Embolism
Mean61.8 (42 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Acute Pulmonary Embolism
Female3
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Acute Pulmonary Embolism
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White3
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Acute Pulmonary Embolism
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
D-dimer
D-dimer(ng/ml)Acute Pulmonary Embolism
Mean2814 (290 to 10000)
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Jul 2022, 38 months.

Results were first posted in Mar 2026, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2019
First posted
Jul 17, 2019
StartActual
May 13, 2019
Primary completionActual
Jul 19, 2022
CompletionActual
Aug 26, 2024
Results first posted
Mar 18, 2026
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04022915
Lead sponsor
Peter Caravan
Responsible party
Peter Caravan (Associate Professor of Radiology, Massachusetts General Hospital) — Sponsor-investigator
First posted
Jul 17, 2019
Start date
May 13, 2019
Primary completion
Jul 19, 2022
Completion
Aug 26, 2024
Results posted
Mar 18, 2026
Last update
Mar 18, 2026

Study contacts

Tilo Winkler, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Copper Cu 64 FBP8

Start the discussion